2. Signaling Pathways
  3. Immunology/Inflammation
  4. VAP-1

VAP-1

Vascular adhesion protein-1 (VAP-1); Semicarbazide-sensitive amine oxidase (SSAO); Amine oxidase copper-containing 3 (AOC3)

VAP-1 is a is a dual-function protein with adhesion properties and semicarbazide-sensitive monoamine oxidase (SSAO) activity. VAP-1 is involved in leukocyte-subtype-specific rolling under physiological shear. And VAP-1 catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. Its catalytic activity can lead to cellular oxidative stress, which has been implicated in several pathologies (atherosclerosis, diabetes, and Alzheimer's disease).

VAP-1 Related Products (5):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99323
    Timolumab
    		Inhibitor 98.56%
    Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases.
    Timolumab
  • HY-P99526
    Vapaliximab
    		Inhibitor
    Vapaliximab (2D10) is a monoclonal antibody against human VAP-1.
    Vapaliximab
  • HY-117833
    PXS-4681A
    		Inhibitor
    PXS-4681A is a potent, selective, irreversible and orally active semicarbazide-sensitive amine oxidase (SSAO; VAP-1) inhibitor with a Ki of 37 nM. PXS-4681A shows highly selectivity over related amine oxidases, ion channels, and seven-transmembrane domain receptors. PXS-4681A has anti-inflammatory effects.
    PXS-4681A
  • HY-157530
    VAP-1-IN-3
    		Inhibitor
    VAP-1-IN-3 (compound 136) is a potent amine oxidase vascular adhesion protein-1 (VAP-1) inhibitor, with an IC50 of 0.13 μM for VAP-1 isolated from bovine plasma. VAP-1-IN-3 can be used for the research of inflammatory.
    VAP-1-IN-3
  • HY-142444
    SSAO/VAP-1 inhibitor 1
    		Inhibitor
    SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3).
    SSAO/VAP-1 inhibitor 1